“We are very excited to establish this joint venture with Arbele Limited to accelerate our clinical programs in cellular therapy,” stated David Jin, M.D., Ph.D., chief executive officer and president of Avalon GloboCare Corp. “Arbele’s strong proprietary technology platform in designing and production of non-viral, transposon-engineered, multi-targeted CAR will allow us to generate next-generation, better and safer CAR-T and CAR-NK cellular therapeutics. This joint venture will strengthen our core technological capabilities, enrich our intellectual properties, as well as further establish our leadership in the field of cellular immunotherapy,”
